linjc16/ctgov huggingface dataset:
Alternate-Day Buprenorphine Administration. Phase VI - 7

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine if four times a subject's daily maintenance dose will hold for 96 hours without changes in agonist and antagonist effects.

Official Title
-----------------
Alternate-Day Buprenorphine Administration. Phase VI

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 51 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Drug use |  |  | 
| Opioid withdrawal |  |  | 
| Opioid agonist effects |  |  | 
| Dose identification |  |  | 
| Pupil diameter |  |  |
T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease

Study Overview
=================
Brief Summary
-----------------
On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver disease.

Official Title
-----------------
T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease

Conditions
-----------------
NAFLD, Heart Failure, Valvular Disease, Coronary Disease

Intervention / Treatment
-----------------
* Diagnostic Test: T1 mapping on Cardiovascular Magnetic Resonance Studies


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Referred for Cardiovascular Magnetic Resonance Imaging Exclusion Criteria: Non-compatible Devices

Ages Eligible for Study
-----------------
Minimum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: T1 mapping on Cardiovascular Magnetic Resonance Studies|On clinically indicated Cardiovascular Magnetic Resonance Imaging Studies, native T1-times and extracellular volume will be determined|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation NAFLD and liver T1mapping | Correlation NAFLD risk score and liver T1-mapping (native and ECV9 | cross-sectional within one year |
The Role of HMGB-1 in Chronic Stroke

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to measure the presence of HMGB-1 and other proteins in the blood across five time points after stroke, and to determine if their presence correlates with rate of stroke recovery.

Detailed Description
-----------------
Stroke, cerebrovascular accident, is the leading cause of brain injury and the leading cause of permanent disability. The acute pathophysiology of stroke depends on the innate immune response, which arises from mostly pro-inflammatory cascades. The chronic pathophysiology of stroke is less clear as the innate inflammatory response fades and matures into an adaptive immune response. HMGB-1 is a serum cytokine that has been found with persistent elevated levels for weeks to months after neurological insult in preclinical experiments, and may retard functional recovery. Elucidation of the relationship between HMGB-1 levels and the rate of functional recovery after stroke could lead to a better understanding of the systemic inflammatory response and more targeted therapeutic interventions.

Official Title
-----------------
Pilot Study of the Role of HMGB-1 in Retarding Recovery in Chronic Stroke

Conditions
-----------------
Cerebrovascular Accident, Cerebral Stroke, Stroke, Acute

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients admitted to the stroke service at Northshore and LIJ Medical Centers Patients 18 years of age or older Exclusion Criteria: Patients < 18 years of age

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokine levels (HMGB-1) in plasma samples |  | day 1, day7, day 14, day 30, day 90 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| NIH and Rankin Clinical Measures of functional recovery |  | day 1, day7, day 14, day 30, day 90 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Stroke, Cerebrovascular Accident, HMGB-1, cytokines, functional recovery, inflammation, immune response
The Effect of High Dose Salbutamol on Muscle Performance

Study Overview
=================
Brief Summary
-----------------
Many athletes use beta2-agonists as treatment of airway hyperresponsiveness during exercise. High dose beta2-agonists may have an ergogenic effect on exercise performance. We hypotheis that the beta2-agonist, salbutamol, taken in high doses can improve muscle power and recovery during exercise in well-trained athletes.

Official Title
-----------------
The Effect of High Dose Salbutamol on Dynamic and Isometric Muscle Power and Recovery in Well-trained Males

Conditions
-----------------
Ergogenic Effects of Salbutamol in Healthy Males

Intervention / Treatment
-----------------
* Drug: salbutamol
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males age 18-45 training frequency > 10 hrs/wk informed consent Exclusion Criteria: smoker or former smoker chronic diseases, as well as asthma allergy to the study drugs intake of any form of medicin or inhibited drugs during the study use of beta2-agonist 14 days before the intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |
| Active Comparator: Salbutamol<br> | Drug: salbutamol<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle power |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Muscle recovery |  |  |
Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Study Overview
=================
Brief Summary
-----------------
Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice

Official Title
-----------------
Secotex®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Conditions
-----------------
Prostatic Hyperplasia

Intervention / Treatment
-----------------
* Drug: Secotex®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients of any age with a diagnosis of symptomatic Benign Prostatic Hyperplasia (BPH) Patients with symptoms, that according to physician require medical treatment to improve quality of life Patients could be naive to treatment or could be on treatment with other drugs but have not responded adequately to treatment Exclusion Criteria: Patients with known hypersensitivity to Tamsulosin, or any other component of the product Patients with a history of orthostatic hypotension or severe liver failure
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Benign prostatic hyperplasia patients<br> | Drug: Secotex®<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with adverse events |  | up to 6 months |
Analgesia After Cesarean Section

Study Overview
=================
Brief Summary
-----------------
Magnesium sulphate is the first line therapy for the management of preeclampsia and eclampsia in obstetrics. Perioperative administration of magnesium sulphate has been proved to be an effective as an analgesic adjuvant. The investigators evaluated the analgesic effect of magnesium in parturients undergoing Cesarean section.

Conditions
-----------------
Preeclampsia, Pregnancy

Intervention / Treatment
-----------------
* Drug: Magnesium Sulphate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: parturients undergoing Cesarean section

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group N<br>parturients who had undergone Cesarean section under the diagnosis of non-preeclampsia | |
| Group P<br>parturients who had undergone Cesarean section under the diagnosis of preeclampsia | Drug: Magnesium Sulphate<br>* Magnesium sulphate was infused for the management of preeclampsia at perioperative period.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change of numeric rating scale (NRS) of postoperative pain during postoperative period |  | postoperative 1, 2, 3, and 4 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| incidence of stopping of intravenous PCA during postoperative 4 days |  | during postoperative 4 days | 
| serum magnesium level of group P |  | preoperative 1 h and postoperative 1 day |
Development of the Eating Behaviour Lapse Inventory Survey Singapore (eBLISS):An Exploratory Mixed-method Study

Study Overview
=================
Brief Summary
-----------------
An exploratory mixed-method study will be conducted to develop an instrument for early detection and prevention of overconsumption.

Official Title
-----------------
Development of the Eating Behaviour Lapse Inventory Survey Singapore (eBLISS):An Exploratory Mixed-method Study

Conditions
-----------------
Eating Behavior

Intervention / Treatment
-----------------
* Behavioral: eBLISS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Above the legal age of 21 years old Have a BMI ≥ 23kg/m2 Able to understand and read English language Uses a smart phone that can download apps Able to provide informed consent Exclusion Criteria: Diagnosed with a pre-existing psychological disorder such as anxiety and depression except binge eating disorder Participating in a concurrent weight management intervention that is beside the usual care

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: eBLISS|a novel instrument -Eating Behaviour Lapse Inventory Survey Singapore (eBLISS)- will be developed|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-regulation of Eating Behaviour Questionnaire (SREBQ) |  | 2021-2023 |
Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to estimate the acute effect of hyperglycemia on Very-Low-Density-Lipoprotein-triglyceride(VLDL-TG) secretion.

Official Title
-----------------
Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) Metabolism During Acute Hyperglycemia

Conditions
-----------------
Type 1 Diabetes

Intervention / Treatment
-----------------
* Other: Hyperglycemia


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 1 diabetes Age 18-50 years Exclusion Criteria: Smoking Alcohol abuse Use of medications (except insulin in diabetics)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Type 1 diabetes<br> | Other: Hyperglycemia<br>* Hyperglycemia with a blood glucose of 15 mmol/L<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) secretion | Very-Low-Density-Lipoprotein-Triglyceride(VLDL-TG) kinetics over a single study day | 8 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 1 diabetes, Very-Low-Density-Lipoprotein(VLDL), Hyperglycemia
Transition From Hospital to Home in Solid Organ Transplant (SOT)

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the influences of discharge teaching and care coordination on how ready a parent is to take their child home from the hospital after a solid organ (kidney, heart and liver) transplant. This study will also look into how the parent handles coping, utilization of healthcare resources, and parent adjustment 3 weeks after discharge from the hospital.

Detailed Description
-----------------
Parents of children that have received a heart, kidney or liver transplant will be asked to participate in this protocol. Involvement in this study involves completion of questionnaires prior to the child being discharged from the hospital. Three weeks after discharge, there will also be a follow-up phone call to complete more questionnaires. Readiness for hospital discharge is a under-investigated topic in pediatric solid organ transplant patients, despite the increasing number of pediatric patients undergoing transplant surgery. Results from this study will be used to develop an intervention program to promote readiness for hospital discharge in parents of children who receive a solid organ transplant.

Official Title
-----------------
The Transition From Hospital to Home in Parents of Solid Organ Transplant Recipients

Conditions
-----------------
Solid Organ Transplant

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: parents of children who have undergo a heart, kidney, or liver transplant English Speaking Parents are 18 years of age or older Exclusion Criteria: parents with significant cognitive or communication impairment that would not allow them to complete the questionnaires parent whose child is receiving their 2nd or 3rd organ transplant

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SOT<br>Patients that have had a solid organ transplant | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the influences of care coordination and discharge teaching on readiness for discharge in solid organ transplant recipients |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the relationship of parent readiness for hospital discharge with coping, utilization of healthcare resources, medication adherence, and parent adjustment following hospital discharge |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
solid organ transplant, hospital discharge
A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Study Overview
=================
Brief Summary
-----------------
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Official Title
-----------------
A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin

Conditions
-----------------
Hyperlipidemia

Intervention / Treatment
-----------------
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening LDL-C < 6.0 mmol/l Triglyceride level < 5.0 mmol/l. Exclusion Criteria: Subjects receiving higher than usual maintenance doses of Lipid Lowering Therapy (LLT) at screening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Atorvastatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin. |  |  |
To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of Mediclore®, as an antiadhesive barrier, which is made of Poloxamer, Gelatin and Chitosan.

Detailed Description
-----------------
to evaluate the efficacy and safety of Mediclore®, as an antiadhesive barrier

Official Title
-----------------
To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Intrauterine Surgery in Patient With Gynecological Disease, a Multicenter, Randomized, Double- Blinded Study

Conditions
-----------------
Gynecologic Disease

Intervention / Treatment
-----------------
* Device: Mediclore® (adhesion barrier)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: the patients with submucosal myomas, endometrial polyps, intra-uterine adhesion, uterine septa, dysfunctional uterine bleeding Written informed consent Patients without clinically significant lab Exclusion Criteria: having enrolled another clinical trials within 1 month Immunosuppression or autoimmune disease Anticoagulant, general steroids within a week from surgery Incompatible medications Serious diseases (heart failure, renal failure, liver failure, uncontrolled hypertension, diabetes mellitus, coagulation deficiencies)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mediclore®<br>adhesion barrier Mediclore 5cc, to apply medical device fully around intrauterine surgery area | Device: Mediclore® (adhesion barrier)<br> <br> |
| No Intervention: No treatment<br>standard treatment for surgery | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adhesion incidence rate following 4 weeks |  | 4weeks |
Assessment of DNA Damage Due to Ionizing Radiation

Study Overview
=================
Brief Summary
-----------------
detection of DNA damage due to occupational exposure to low dose ionizing radiation using comet assay technique and genotyping of certain DNA repair genes to detect inherited polymorphism.

Official Title
-----------------
Assessment of DNA Damage and Capacity of DNA Repair System Among Nuclear Medicine and Clinical Oncology Workers Exposing to Ionizing Radiation

Conditions
-----------------
Occupational Exposure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • The radiation exposed workers will include nurses, technicians and physicians. These persons will be occupationally exposed to different radiation sources. Exclusion Criteria: History of diagnostic X-rays, radiotherapy and/or chemotherapy 12 months prior to sampling.
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detection of DNA damage due to occupational exposure to ionizing radiation | comet assay technique will be used | 6 month |